ClinicalTrials.gg
CompletedNCT01896726Updated Jun 6, 2017Results posted

A Study of Baricitinib and Birth Control Pills in Healthy Females

A Phase 1 interventional study of Baricitinib and Microgynon in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The main purpose of this study is to find out how the body absorbs and breaks down a common birth control pill called Microgynon when it is given with the study drug called baricitinib. Safety and the body's ability to tolerate baricitinib and Microgynon will also be studied. The study will last approximately 6 weeks for each participant.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal females currently successfully using non-hormonal methods of including tubular ligation, cervical vault cap, diaphragm, or non-hormonal coil with spermicide will be required in addition to use a second approved method of contraception for the duration of the study [that is (i.e.), a male sexual partner who agrees to use a male condom with spermicide; a sterile sexual partner; or abstinence (participants reporting abstinence who become sexually active while on the study must agree to use other additional barrier methods of contraception)]. The pregnancy test result must be negative at screening and at each check-in visit. Participants must have a regular menstrual cycle of approximately 28 days duration for at least 4 previous cycles prior to screening
  • females, or women not of due to surgical sterilization (at least 3 months after surgical hysterectomy, or at least 3 months after bilateral oophorectomy or bilateral tubal occlusion with or without hysterectomy) confirmed by medical history, or menopause. Menopausal women include women with spontaneous amenorrhea for at least 12 months or amenorrhea not induced by a medical condition such as anorexia nervosa and/or not taking medications during that time of amenorrhea [example (e.g.), oral contraceptives (OCs), hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators, or chemotherapy]. Postmenopausal status should be confirmed by a serum follicle-stimulating hormone level at screening greater than 40 international units per liter (IU/L)
  • Have a of 18 to 30 kilograms per square meter (kg/m\^2), inclusive

Exclusion criteria

Exclusion Criteria:

  • Have a positive pregnancy test or are lactating
  • Are currently enrolled in, have completed or discontinued within the last 90 days from a clinical trial involving a study drug; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Are persons who have previously completed or withdrawn from this study or any other study investigating baricitinib, and have previously received the study drug
  • Have known allergies to baricitinib or Microgynon (containing ethinyl estradiol and levonorgestrel) or related compounds
  • Have used or intend to use drugs or substances that are known to be inducers or inhibitors of cytochrome P450 3A (eg, St. John's wort, rifampin, ketoconazole) within 30 days prior to the first dose
  • Have taken OCs within 3 months, implanted within 6 months, injectable contraceptives within 12 months, or topical controlled delivery contraceptives (patch) or hormonal coils within 3 months prior to the study
  • Have a history or presence of any thromboembolic disease, recurrent jaundice, acute or chronic liver disease, hormonally-induced migraines, undiagnosed vaginal bleeding, significant hyperlipidemia, and mammary, endometrial, or hepatic carcinoma (known or suspected)
  • Smokes more than 10 cigarettes per day
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Baricitinib + Microgynon

    Microgynon \[30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel\] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.

    Drug: Baricitinib · Drug: Microgynon

Interventions

  • Administered orally

    Also known as: LY3009104

  • DrugMicrogynon

    Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol

    Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

  2. PK: Cmax of Levonorgestrel

    Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol

    Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

  4. PK: AUC(0-∞) of Levonorgestrel

    Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

07

Results

Posted Apr 21, 2017

Participant flow

Treatment Period 1 (Days 1-22)
Participant flow — Treatment Period 1 (Days 1-22)
MilestoneBaricitinib + Microgynon
Started20
Received microgynon20
Completed20
Not completed0
Treatment Period 2 (Days 23-31)
Participant flow — Treatment Period 2 (Days 23-31)
MilestoneBaricitinib + Microgynon
Started20
Received at least 1 dose of baricitinib20
Received microgynon18
Completed18
Not completed2
Withdrew: Adverse event1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol
Time frame:
Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
Reported as:
Geometric mean · picograms/milliliter (pg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol
picograms/milliliter (pg/mL)Microgynon AloneBaricitinib + Microgynon
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol63.8 ± 2359.7 ± 24
PrimaryPK: Cmax of Levonorgestrel
Time frame:
Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
Reported as:
Geometric mean · pg/mL
PK: Cmax of Levonorgestrel
pg/mLMicrogynon AloneBaricitinib + Microgynon
PK: Cmax of Levonorgestrel3390 ± 343340 ± 26
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol
Time frame:
Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
Reported as:
Geometric mean · picograms*hour/milliliter (pg*hr/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol
picograms*hour/milliliter (pg*hr/mL)Microgynon AloneBaricitinib + Microgynon
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol694 ± 24697 ± 25
PrimaryPK: AUC(0-∞) of Levonorgestrel
Time frame:
Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
Reported as:
Geometric mean · pg*hr/mL
PK: AUC(0-∞) of Levonorgestrel
pg*hr/mLMicrogynon AloneBaricitinib + Microgynon
PK: AUC(0-∞) of Levonorgestrel48200 ± 5842400 ± 45

Adverse events

Collected over Baseline through study completion (up to Day 40).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Microgynon Alone—0/20 (0%)3/20 (15%)
Baricitinib—0/20 (0%)4/20 (20%)
Baricitinib + Microgynon—1/18 (5.6%)4/18 (22.2%)
Most frequent serious events
Most frequent serious events
EventMicrogynon AloneBaricitinibBaricitinib + Microgynon
Maternal exposure during pregnancyInjury, poisoning and procedural complications0/200/201/18
Most frequent other events
Most frequent other events
EventMicrogynon AloneBaricitinibBaricitinib + Microgynon
Back painMusculoskeletal and connective tissue disorders1/202/200/18
HeadacheNervous system disorders2/201/200/18
DiarrhoeaGastrointestinal disorders0/200/201/18
FlatulenceGastrointestinal disorders0/200/201/18
Vulvovaginal candidiasisInfections and infestations0/200/201/18
Decreased appetiteMetabolism and nutrition disorders0/201/201/18

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Baricitinib + Microgynon
Mean44.1 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib + Microgynon
Female20
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib + Microgynon
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib + Microgynon
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White17
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Baricitinib + Microgynon
United Kingdom20
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2013
First posted
Jul 11, 2013
Start
Jul 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01896726
Responsible party
Sponsor
First posted
Jul 11, 2013
Start date
Jul 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion